Print Page     Close Window     

SEC Filings

10-Q
APTEVO THERAPEUTICS INC. filed this Form 10-Q on 11/13/2017
Entire Document
 

 

“including” are not limiting; (b) “hereof, “hereto”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (c) words of one gender include the other gender; (d) references to a contract or other agreement mean such contract or other agreement as from time to time amended, modified or supplemented; (e) references to a Person are also to its permitted successors and assigns; (f) references to an “Article”, “Section”, “Exhibit” or “Schedule” refer to an Article or Section of, or an Exhibit or Schedule to, this Agreement, unless expressly stated otherwise; and (g) references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.

1.77Other Definitions.  The following capitalized terms have the meaning ascribed to them in the corresponding identified section of this Research Agreement (unless otherwise provided):

Definition

Section

4-1BB

1.21

4-1BB Binding Domain

1.21

[***]

1.21

[***]

1.21

Acquired Third Party IP

4.9.2

Agreement

Preamble

Alligator

Preamble

Alligator CMO

6.2.2

Alligator Indemnitee

13.1

Allocable Percentage of Revenue / APR

14.4.1

Aptevo

Preamble

Aptevo Indemnitees

13.2

Aptevo Option

4.8

Aptevo Option Product

4.8

Best Offer

7.3.2

BD Committee

7.5.1

Board of Directors

1.22.1

Budget Forecast

2.3.1

CEO Negotiation Period

15.4.2

CEOs

15.4.2

[***]

3.1.10

CMC

1.25

[***]

3.1.10

CMOs

2.1.3(a)

Competing Product

2.6.1

Confidential Information

5.1

Consideration Period

14.2.1(b)

Continuing Party

14.3.1(b)

CROs

2.1.3(a)

13

[*** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.



© Aptevo BioTherapeutics, LLC.